Acrivon Therapeutics Inc

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing precision medicines for oncology and inflammatory diseases utilizing its proprietary Generative artificial intelligence (AI)-driven, Phosphoproteomics Acrivon Predictive Precision Proteomics (AP3) platform. Its lead program, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase II trial for endometrial cancer (EC). It is advancing ACR-7280, its next AP3-enabled innovation program, a first-in-class, oral, highly selective CDK11 inhibitor development candidate, in IND-enabling studies. Its immunology and inflammation pipeline, ACR-525, a Phase II-ready, oral, highly selective JAK1 inhibitor. Additionally, the Company has a preclinical PKCθ inhibitor preclinical program, an attractive target for T-cell-driven autoimmune and inflammatory diseases, with the potential to be developed in combination with ACR-525 and other I&I therapies.